Senolytic-mediated elimination of head and neck tumor cells
induced into senescence by cisplatin

Fereshteh Ahmadinejad1*, Tasia Bos2*, Bin Hu3, Erin Britt2, Jennifer Koblinski3, Andrew J. Souers4, Joel D. Leverson4, Anthony C. Faber2, David A. Gewirtz5#, Hisashi Harada2#

1: Department of Human and Molecular Genetics, School of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
2: Philips Institute for Oral Health Research, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
3: Cancer Mouse Models Core, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
4: AbbVie, North Chicago, Illinois
5: Department of Pharmacology and Toxicology, School of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia

*Equally contributed to this work
Running title: Recovery and elimination of senescent tumor cells

Keywords: senescence, chemotherapy, senolytic, head and neck cancer, ABT-263

#To whom correspondence should be addressed at:
Massey Cancer Center, Virginia Commonwealth University
401 College St., Richmond, VA 23298

Phone: 804-828-9523, 804-628-0064
Email: david.gewirtz@vcuhealth.org, hharada@vcu.edu

The number of text pages: 23
The number of tables: 0
The number of figures: 7
The number of references: 86
The number of words in the Abstract: 231
Introduction: 711
Discussion: 1445
Abstract:

Therapeutic outcomes achieved in head and neck squamous cell carcinoma (HNSCC) patients by concurrent cisplatin-based chemoradiotherapy initially reflect both tumor regression and tumor stasis. However, local, and distant metastasis and disease relapse are common in HNSCC patients. In the current work, we demonstrate that cisplatin treatment induces senescence in both p53 wild-type HN30 and p53 mutant HN12 head and neck cancer models. We also show that tumor cells can escape from senescence both in vitro and in vivo. We further establish the effectiveness of the senolytic, ABT-263 (Navitoclax), in elimination of senescent tumor cells after cisplatin treatment. Navitoclax increased apoptosis by 3.3-fold (p ≤ 0.05) at Day 7 compared to monotherapy by cisplatin. Additionally, we show that ABT-263 interferes with the interaction between BCL-X\(_L\) and BAX, anti- and pro-apoptotic proteins, respectively, followed by BAX activation, suggesting that ABT-263 induced apoptotic cell death is mediated through BAX. Our in vivo studies also confirm senescence induction in tumor cells by cisplatin, and the promotion of apoptosis coupled with a significant delay of tumor growth after sequential treatment with ABT-263. Sequential treatment with cisplatin followed by ABT-263 extended the humane endpoint to ~130 days compared to cisplatin alone, where mouse survived ~75 days. These results support the premise that senolytic agents could be utilized to eliminate residual senescent tumor cells after chemotherapy and thereby potentially delay disease recurrence in head and neck cancer patients.
Abbreviations:

Cis       Cisplatin
HNSCC     Head and Neck Squamous Cell Carcinoma
SASP      Senescence-associated secretory phenotype
SA-β-Gal  Senescence-associated beta galactosidase
BCL-2     B-cell lymphoma-2
BCL-X_L    B-cell lymphoma-x large
BH3       BCL-2 homology 3
4NQO      4-nitroquinoline 1-oxide
FACS      fluorescence activated cell sorting

Significance Statement: Disease recurrence is the most common cause of death in head and neck cancer patients. BCL-X_L inhibitors such as ABT-263 (Navitoclax) have the capacity to be used in combination with cisplatin in head and neck cancer patients to eliminate senescent cells and possibly prevent disease relapse.
Introduction

Head and neck cancer is the sixth most common type of malignancy worldwide, with head and neck squamous cell carcinomas (HNSCCs) accounting for >90% of cases. HNSCC incidence largely correlates with tobacco and alcohol usage and is often diagnosed in advanced stages (Leemans et al., 2011). There is also a rapidly increasing incidence of a human papillomavirus-related (HPV+) subtype of HNSCC, which arises in a younger patient demographic that includes many never-smokers (Donà et al., 2020).

Head and neck cancer is generally treated with a combination of surgery, radiation and chemotherapy, with cisplatin being a primary therapeutic modality (Cramer et al., 2019; Chow, 2020). Despite recent advances in cancer therapeutic approaches, 40% and 20% of patients with HPV-negative HNSCC experience locoregional and distant failure, respectively, after cisplatin-based chemoradiotherapy. While head and neck cancer is generally responsive to initial therapy, the disease almost invariably recurs, often becoming refractive to further therapy (Gibson et al., 2005; Argiris et al., 2008). An accumulating body of evidence has shown that cancer relapse often occurs after both conventional and advanced therapeutic approaches, where the therapy results in an accumulation of non-proliferative residual cancer cells (Goss and Chambers, 2010; Kareva, 2016). The cross talk between these tumor cells and their microenvironment can result in escape from the growth-arrested state via recovery of the cellular proliferative capacity, leading to disease recurrence (Sosa et al., 2014; Yeh and Ramaswamy, 2015).

The mechanism(s) whereby the residual cells maintain their long-term survival is poorly understood, but a significant number of recent studies have shown that transient senescence, the tumor cells’ primary response to subtoxic doses of chemotherapy and/or radiation, can potentially contribute to cancer recurrence (Demaria et al., 2017; Duy et al., 2021). Senescence in cancer was
first described as the limited proliferative capacity of tumor cells in response to activated oncogenes, oxidative stress, specific cytokines and chemokines, and DNA damage induced by chemicals such as chemotherapeutic agents (therapy-induced senescence) (Ewald et al., 2010). Senescence was originally considered to represent an irreversible form of growth arrest; however, studies in various cancer models including lung, prostate, and breast (Elmore, 2005; Roberson et al., 2005; Wang et al., 2013; Chitikova et al., 2014; Saleh et al., 2019) have shown that while therapy-induced senescence in cancer cells is durable, it does not actually represent a permanent form of growth arrest. Consequently, the senescence phenotype is not necessarily a favorable outcome of cancer therapy. In addition to cell cycle arrest, senescence is characterized by pronounced alterations in cells morphology, increased lysosomal biogenesis with β-galactosidase expression, facultative heterochromatin condensation and foci formation H3K9Me3 (SAHF), and secretion of various inflammatory cytokines and chemokines such as IL-6, IL-8, IL-1β, and MMP3, reflecting the senescence-associated secretory phenotype (SASP) (Sharpless and Sherr, 2015; Hernandez-Segura et al., 2018).

Senolytics are a relatively new class of drugs that have been shown to selectively induce cell death in senescent cells (Baker et al., 2011; Saleh, Carpenter, et al., 2020). One of the extensively characterized and effective senolytics is a BH3 mimetic, specifically the BCL-2 and BCL-XL inhibitor known as ABT-263 (Navitoclax) (Saleh, Carpenter, et al., 2020). Navitoclax has been shown to have high affinity towards the hydrophobic pocket of anti-apoptotic proteins such as BCL-2 and BCL-XL (Chen et al., 2011). Upon binding, pro-apoptotic proteins such as BAX/BAK are released from these anti-apoptotic proteins, resulting in the activation of pro-apoptotic BAX/BAK to initiate apoptosis by releasing cytochrome c from mitochondria to the cytosol followed by caspase activation (Mérino et al., 2012). Studies have shown that anti-
apoptotic BCL-2 family proteins are often overexpressed in cancer cells after chemotherapy or radiation, which is thought to be a central mechanism by which cancer cells survive beyond first-line therapies and, ultimately leading to metastasis and cancer recurrence (Raffo et al., 1995). Navitoclax has demonstrated activities in investigational clinical trials both as a single agent and in combination with chemotherapy or radiation in different cancer types (Rudin et al., 2012; Puglisi et al., 2021).

The current studies demonstrated transient senescence induction by cisplatin in human and murine head and neck cancer cell lines and in head and neck cancer mouse models. Furthermore, escape from senescence was observed in experimental models of head and neck cancer whereas navitoclax was shown to have senolytic activity both in culture and in tumor bearing animals. Mechanistic studies identified BCL-X<sub>L</sub> as a primary target of navitoclax for the killing of senescent head and neck cancer cells. BCL-X<sub>L</sub> was induced after cisplatin treatment, whereas navitoclax administration released BAX from the BCL-X<sub>L</sub>/BAX complex to induce apoptosis specifically in senescent cells. Finally, sequential treatment with cisplatin followed by navitoclax significantly delayed tumor growth and prolonged survival in the mouse model of head and neck cancer.
**Materials and methods**

**Cell lines and drug treatments**

Investigations were carried out on two HPV-negative human HNSCC cell lines, HN30 (wild-type p53) and HN12 (truncated non-functional p53), which were provided by Dr. Andrew Yeudall (Augusta University). Cells were cultured in DMEM (Thermo Fisher, 10569010) supplemented with 10% (v/v) fetal bovine serum (Gemini, 26140), 100 U/ml penicillin G sodium and 100 µg/ml streptomycin sulfate (Thermo Fisher, 15140148) at 37ºC and 5% CO2. HN30 BAX and BAK knock-down cell lines were established by viral particles generated by HEK293T cells after co-transfection with appropriate shRNA plasmids, psPAX2 (addgene, 12260), and pMD2.G (Addgene, 12259) with EndoFectin-Lenti (GeneCopoeia, EF013). Next, viral supernatants were collected and used for HN30 cells transduction. Finally, transduced cells were selected by 2 µg/ml puromycin in several passages for a pure knocked-down population. Cisplatin (Sigma-Aldrich, 15663-27-1, ≥98% (HPLC) was dissolved in PBS, and ABT-263 (AbbVie Inc), ABT-199 (APExBio, A8194, 98.07% HPLC), and A-1155463 (APExBio, B6163, 98.78% HPLC) were dissolved in DMSO and administered in the dark at the desired concentrations. Drugs are stable after preparation and were kept at -20ºC in the dark.

**Cell viability and clonogenic survival assays**

Cell viability was determined by monitoring the number of viable cells over time using trypan blue dye exclusion staining before, during, and after drug treatment. Cells were treated with 5 µM cisplatin for 24 hours and were collected by trypsinization at specific time points, and stained with 0.4% trypan blue (Sigma, T8154) and counted using hemocytometer under light microscopy. For clonogenic survival assays, cells were seeded at a low density at 5 x 10^3/10 cm dish or 1,000/6-well plates, then treated 2 µM ABT-263, ABT-199, A-1155463 or vehicle for 24 hours. Colony
formation was monitored over time, and at the experiment end point (at Day 14, when the vehicle-treated condition formed distinct colonies with more than 50 cells), colonies were fixed with 100% methanol, air-dried, stained with 0.05% crystal violet and counted using a colony counter (COLOCOUNT Discovery Technology Intl).

**SA-β-galactosidase Staining/Enrichment**

Histochemical staining of SA-β-gal was performed as previously described (Dimri et al., 1995; Debacq-Chainiaux et al., 2009). Images were taken by a bright field inverted microscope (Olympus inverted microscope IX70, 20x objective, Q-Color3™ Camera; Olympus, Tokyo, Japan). The C12FDG flow cytometry was performed using the protocol described by Debacq-Chainiaux et al (Debacq-Chainiaux et al., 2009). At the specific time points, cells were collected, washed with PBS, and analyzed by flow cytometry (using BD FACSCanto II and BD FACSDiva software at the Virginia Commonwealth University Flow Cytometry Core Facility). Similarly, for immunofluorescent staining of C12FDG, cells were exposed to 100 nM of bafilomycin A1 (Sigma Aldrich, B1793, >90% HPLC) for one hour, and after increasing the lysosomal PH, cells were exposed to 100 µM C12FDG (Thermo Fisher, D2893) for 2 hours. After washing with PBS, nuclei were stained with Hoechst 33342 (Thermo Fisher, 33342) for 20 minutes in complete media. Images were taken using the Olympus inverted microscope. To enrich the senescent population, cells were seeded at high density for 1-2 x 10^6/150 mm dish and cultured overnight. The next day, cells were treated with cisplatin, and at the indicated time points, they underwent C12FDG staining as described above. Finally, cells were sorted by FACS. All the above experiments were performed at Day 5 after treatment with 5 µM cisplatin for 24 hours.

**Total cell lysates, subcellular fractionation, and Western blotting**
Total cell lysates were prepared using the CHAPS buffer [20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM dithiothreitol (DTT), 1% CHAPS (3-[(3-Cholamidopropyl) dimethylammonio] 1-propanesulfonate)]. The mitochondria fraction was prepared with Qproteome Mitochondria Isolation Kit (Qiagen, 37612) according to the manufacture’s protocol. Western blotting was performed as described (Sharma et al., 2014). Antibodies used in 1:1000 dilution: cleaved PARP (Cell Signaling, 5625), cleaved caspase 3 (Cell Signaling, 9664), GAPDH (Cell Signaling, 5174), BCL-2 (Sigma, B3170), BCL-X\(_L\) (Cell Signaling, 2764), BAX (Cell Signaling, 2772), BAK (Cell Signaling, 12105), p53 (Santa Cruz, 23959), p21 (Cell Signaling, 2947), COX-IV (Cell Signaling, 4850).

**Co-immunoprecipitation**

BCL-X\(_L\) (Cell Signaling, 2764) or BAX (Santa Cruz, 23959) primary antibodies (1:100 dilution) were added to equal amounts of total lysates extracted from treated and non-treated cells. After an overnight incubation at 4ºC, Protein A/G beads (Thermo Fisher, 53132) were added for 1 hour incubation at 4ºC to precipitate the protein-antibody complexes. Samples were centrifuged, washed, and resuspended in 50/50 CHAPS buffer and 2X SDS-loading buffer. After boiling the samples for 5 mins, they were subjected to SDS-PAGE followed by Western blotting as described above.

**Cell cycle, Annexin-V/PI staining, and γ-H2AX analysis**

Cell cycle analysis was performed based on propidium iodide staining (Saleh et al. 2019), and apoptosis quantification was done using AnnexinV-FITC apoptosis detection kit (556547, BD Biosciences, NJ, USA). Cells were seeded at the density of 4 x 10\(^4\) cells per milliliter, treated with 5 µM cisplatin for 24 hours, and harvested at the indicated time points. After washing the samples with PBS, cells were resuspended in 100 µl of 1x Binding Buffer and incubated for 15 min in the
dark at RT. Up to 500 µl of extra binding buffer was added to the final suspension and then the samples were analyzed by flow cytometry. Cell cycle analysis was performed at Day 5 after treatment with cisplatin, and apoptosis was assessed at Day 7. For γ-H2AX analysis, cells were seeded at a density of 4 x 10^4 cells per milliliter, treated with 5 µM cisplatin or vehicle for 24 hours. At Day 5, 2 µM ABT-263 was added to the combination conditions for 48 hours and γ-H2AX induction was monitored by flow cytometry at Day 7. Cells were harvested, fixed with 3.7% formaldehyde and permeabilized with cold methanol. After washing the pellets, cells were incubated with 1:250 dilution of γ-H2AX antibody conjugated to FITC (anti-H2AX (pS139), BD Biosciences, Cat. No. 560443) for 30 minutes.

**Live-cell imaging**

HN30 cells were plated (5 x 10^5 cells per milliliter) in 6-well plates and incubated overnight. After treatment with 5 µM cisplatin or vehicle for 24 hours, the plates were immediately placed on a CytoSMART digital microscopy system inside a humidified CO_2_ incubator at 37 °C. Live time lapse images were taken every 15 min for 48 hours on Day 5 (growth arrested and control cells, respectively) and Day 10 (cells escaping from senescence and recovering their proliferative capacity).

**qRT-PCR**

Cells were plated (5 x 10^5 cells per milliliter) and treated with 5 µM cisplatin for 24 hours. At Day 5, cells were harvested, and total RNA was extracted using RNeasy kit (QIAGEN, 74004) following the manufacturer’s instructions. cDNA was synthesized using iScript cDNA Synthesis Kit (BioRad, 4106228) based on the protocol that manufacture provided. cDNAs from different samples were amplified in technical triplicates using iTaq Universal SYBR® Green Supermix (BioRad, 10000068167) in QuantStudio™ 3 Real-Time PCR System (Thermo Fisher). QuantiTect
primers were purchased from Qiagen: CXCL8: QT0000322; IL-6: QT00083720; IL-1β: QT00021385; MMP3: QT00060025; GAPDH: QT00079247. Relative mRNA expression was determined using the ΔΔCt method.

**In-vivo experiments**

All animal studies were conducted in accordance with Virginia Commonwealth University IACUC guidelines. We first established the mouse oral squamous cell carcinoma (OSCC) cell line, 602, derived from the 4-nitroquinoline-1 oxide (4NQO)-developed tumor on the tongue. Female C57BL/6 mice (5 weeks of age; Envigo) were treated with 50 µg/ml 4NQO-containing water for 16 weeks. Then the drinking water was reverted to regular water until Week 22. When a single lesion on the tongue became ~50 mm³, a tumor was removed and digested, and cells were isolated to establish a cell line. To establish tumors, 1 x 10⁶ of 602 OSCC cells were suspended in 50/50 PBS-Cultrex basement membrane matrix (Cultrex, 3632-005-02) and subcutaneously inoculated into the rear flanks of C57BL/6 female mice (Day 0). When tumor size approached ~100 mm³, mice were randomized in five groups (Day 13, N=6/group) and treated with cisplatin (5 mg/kg) by intraperitoneal injections at Day 13, 16, 20 and 23, then with ABT-263 (80 mg/kg) by oral gavage daily at Day 27-31 and Day 34-38. The second round of treatments was performed with cisplatin at Day 41, 44 and 48, followed with ABT-263 at Day 55-59 and Day 62-66. Tumor volumes were taken by manual caliper measurements.

**Immunohistochemistry**

For cleaved caspase-3 (Cell Signaling, 9664) and γ-H2AX (Cell Signaling, 9718), tumors were fixed in 10% formalin phosphate buffer and performed on BOND RX Fully Automated Research Stainer. Slides were stained overnight at 4°C with cleaved caspase-3 (1:500) or γ-H2AX (1:400) primary antibodies then for 8 min at room temperature with the secondary antibody.
included in the BOND Polymer Refine Detection kit (Leica, DS9800). Slides were mounted with Dako CoverStainer (Agilent). Images were taken on Vectra Polaris Automated Quantitative Pathology Imaging System (Akoya Biosciences) at 20X at the VCU Cancer Mouse Models Core (CMMC). For X-Gal staining, tumors were frozen into OCT molds and cut into 10-micron sections by the VCU Tissue and Data Acquisition and Analysis Core (TDACC).

**Blood analysis and platelet/neutrophil counts:**

Mice treated with vehicle, cisplatin, ABT-263, or a combination of cisplatin and ABT-263 were subjected to Complete Blood Count (CBC) analysis at the indicated time points (Figure 6E). Blood samples (~0.2 ml) were collected by facial vein using EDTA coated syringes and immediately analyzed by hematology analyzer Hemavet 950FS (Drew Scientific, Miami Lakes, FL, USA) at the VCU CMMC.

**Statistical Analysis**

Unless otherwise indicated, all quantitative data is shown as mean ± SD from at least three independent experiments (biological replicates), all of which were conducted in triplicates or duplicates (technical replicates). GraphPad Prism 6.0 software was used for statistical analysis. All data was analyzed using either a one- or two-way ANOVA, as appropriate, with Tukey or Sidak post hoc, with the exception of cell cycle, C₁₂FDG data, and platelet counts which were analyzed with unpaired, student’s t-tests.
Results

Cisplatin induces growth arrest and senescence in head and neck cancer cells

Pharmacokinetic studies have indicated that the highest plasma concentration of cisplatin achieved in patients is 12 µM at 5 minutes after injection, while the plasma concentration decreases to 5.9 µM after 2 hours. Up to 90% of total cisplatin is excreted (depending on the patient’s renal function) in 24 hours. Consequently, initial experiments to investigate the cellular response to cisplatin in head and neck cancer cells involved exposure to clinically relevant concentrations of cisplatin (2, 5 and 10 µM) for 24 hours (Farris et al., 1988; Urien and Lokiec, 2004; Ang et al., 2014). As expected, cisplatin induced a temporary growth arrest after 24 hours of treatment in both HN30 (p53 wild-type) and HN12 (p53-null) head and neck cancer cell lines. As we have reported in other tumor cell models (Saleh et al., 2019; Saleh, Carpenter, et al., 2020), the cells ultimately escaped and recovered their proliferative capacity (Figure 1A). Cell cycle analyses confirmed that both cell lines arrested primarily at the G0/G1 phase (Figure 1B).

The antitumor activity of cisplatin is generally ascribed to the induction of DNA single- and double-strand breaks subsequent to the cross-linking of DNA (Jeon et al., 2008; Basu and Krishnamurthy, 2010; Rezaee et al., 2013). Consistent with the fact that senescence has been suggested to be the primary response of tumor cells to chemotherapeutic agents and cellular stress conditions (Triana-Martínez et al., 2020), we confirmed that cisplatin promotes senescence in our experimental models. This determination was based on a number of characteristics such as morphological changes, qualitative and quantitative measurement of SA-β-gal activity using X-gal staining (Figures 1C, Upper portion) and fluorescence-based labeling with C12FDG (Figures 1C, right panels, and S1), and upregulation of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21 (Figure 1D). Additional senescence markers, specifically heterochromatic...
foci (H3K9Me3) formation (Figure 1C, lower panels) and increased expression of Senescence-Associated Secretory Phenotype (SASP) components such as IL-6, IL-8, and IL-1β, (Figure 1E) further confirmed that cisplatin treatment can promote senescence in HNSCC cells regardless of the p53 status.

**Proliferative recovery in cisplatin-treated HNSCC cells is associated with a decline in senescence markers**

Despite the long-held paradigm that therapy-induced senescence (TIS) is an irreversible and permanent form of growth arrest, which would be consistent with a favorable therapeutic outcome of senescence induction (Shay and Roninson, 2004), our previous studies along with rigorous experiments by other investigators have firmly established that at least a subpopulation of cells can and will evade the senescent arrest and re-emerge with self-renewal capacity (Elmore, 2005; Roberson et al., 2005; Puig et al., 2008; Wang et al., 2013; Chitikova et al., 2014; Saleh, Carpenter, et al., 2020). To interrogate whether this is also the case for head and neck cancer cells induced into senescence by cisplatin, we utilized multiple approaches to investigate the capacity for proliferative recovery from senescence in our experimental models. Live-cell imaging microscopy was utilized to monitor proliferative recovery from cisplatin-induced senescent HN30 cells (Videos S1A, B, and C). A comparison of the morphologic characteristics of cells at different time points established that the emerging population at Day 11 in Video S1C was indeed derived from the senescent population. Further confirmation of the involvement of senescence in recovery was based on the observation that proliferative recovery in our models is associated with diminution of the senescence markers (Figure 2). Specifically, SA-β-gal activity showed a significant reduction after the cells recovered their proliferative capacity (Figure 2A). Similarly, the decline in additional senescence markers such as components of the senescence-associated
secretory phenotype (SASP) (Figure 2B), further indicates that the cisplatin-induced senescent-like state is not sustained.

It is possible that the recovered population originated from a subclone that was resistant to the primary effects of cisplatin de novo rather than via escape from chemotherapy-induced senescence (Beausejour, 2003; Dirac and Bernards, 2003). To confirm that cells can and do recover from chemotherapy-induced senescence, cisplatin-induced senescent cells were labeled with the fluorescent substrate of SA-β-gal, C12FDG, and enriched for the highest ~30% of the C12FDG-positive (SA-β-gal-positive) and morphologically enlarged population using fluorescence-activated cell sorting (FACS). This protocol ensures a highly specific and selective purification of senescent population from a heterogeneous mixture of tumor cells after treatment. The highly C12FDG-positive population was then re-plated and monitored for senescence markers such as proliferative arrest, and SA-β-gal activity. As shown in Figures 2C and 2D, the sorted population recovered proliferative capacity after 16 days accompanied by the suppression of SA-β-gal activity.

**ABT-263 selectively eliminates senescent tumor cells in vitro**

The proliferative recovery in tumor cells re-emerging from a therapy-induced senescent population has been shown to contribute not only to recurrence of a more aggressive form of the disease, but also to acquired resistance to chemotherapy or radiation (Rebbaa, 2005; Yang *et al.*, 2017). Consequently, in an effort to eliminate the cisplatin-induced senescent population, cisplatin-treated HN30 and HN12 cells were exposed to a single dose of ABT-263, an agent that has demonstrated senolytic properties (Sharma *et al.*, 2014; Lafontaine *et al.*, 2021) for 24-hours. A significant decrease in the number of viable cells (Figure 3A) strongly suggests that ABT-263 selectively eliminates cisplatin-treated senescent cells, while showing minimal effects on untreated
cells. Clonogenic survival assays using increasing concentrations of ABT-263 on non-treated tumor cells confirmed that ABT-263 alone, even at higher concentrations, was ineffective in perturbing colony formation for non-senescent tumor cells (Figure S2A). This result was recapitulated with selective inhibitors of BCL-2 (ABT-199) and BCL-XL (A-1155463) (Figures S2B and S2C). In addition, ABT-263 treatment resulted in a significant decrease in the SA-β-gal positive (senescent) population (Figure S2D), further confirming the selective activity of ABT-263 for the senescent population. As we have reported previously in models of non-small cell lung cancer and breast cancer (Alotaibi et al., 2016; Saleh et al., 2019), ABT-263 effectiveness diminishes over time as the treated cells escape senescence and recover their proliferative capacity (Figure S2E, lower panel) in marked contrast to the effectiveness of ABT-263 after a second dose of cisplatin (Figure S2E, upper panel). This observation reaffirms the selectivity of ABT-263 for a senescent cell population.

Consistent with previously published studies on ABT-263 as an apoptosis inducing agent (Tse et al., 2008), there was a significant increase in Annexin-V/PI staining and the apoptosis marker, cleaved-caspase-3, in the combinatorial treatment group (cisplatin followed by ABT-263) compared to cisplatin or ABT-263 alone (Figures 3B and 3C). Taken together, these observations strongly confirm that ABT-263 acts as a selective senolytic in vitro by significantly decreasing the number of cisplatin-induced senescent cells.

The BCL-X<sub>L</sub>/BAX axis is the primary target for cell death induced by ABT-263 in cisplatin-induced senescent HNSCC cells

ABT-263 is known to specifically inhibit the function of the anti-apoptotic BCL-2 and BCL-X<sub>L</sub> proteins to induce apoptotic cell death (Tse et al., 2008). In order to delineate the specificity of the inhibitory activity in head and neck cancer, we treated cisplatin-induced
senescent HN30 cells with a BCL-2 specific inhibitor, ABT-199 and a BCL-XL specific inhibitor, A-1155463. These agents do not have an effect on non-senescent HN30 cells (Figures S3A, S3B, S2A, S2B, and S2C). However, A-1155463, but not ABT-199, eliminated senescent cells, suggesting that BCL-XL is the primary target in senescent HNSCC cells (Figures 4A, and S3A). We further confirmed that ABT-263 and A-1155463-mediated cell death was occurring primarily via apoptosis using Annexin-V staining (Figure 4C). Similar specificity to BCL-XL was also observed in p53-null HN12 cells (Figure 4B, 4D, and S3B) These results strongly suggest that BCL-XL is the primary target of ABT-263-induced senolytic cell death.

In order to further support that the senolytic activity of ABT-263 in head and neck cancer cells was driven by inhibition of BCL-XL, we next determined the expression of major BCL-2 family proteins in cisplatin-induced senescence HN30 cells. The level of the anti-apoptotic protein, BCL-XL, gradually increased following cisplatin treatment (Figure 5A). Consistently, these increases were also observed in the HN12 cells (Figure 5B). Changes of other BCL-2 family proteins were inconsistent (Figures 5A and 5B).

ABT-263 inhibits the interaction of BCL-XL with BAX/BAK, thereby inducing apoptosis (Saleh, Carpenter, et al., 2020). To elucidate the involvement of these executioner pro-apoptotic proteins following ABT-263 treatment, we established stable HN30 cells with shRNA for BAX (shBAX), BAK (shBAK) or scrambled-control (shC) (Figure 5C). Although these cell lines undergo similar induction of senescence following exposure to cisplatin (Figure 5D, bottom), cisplatin-treated shBAX-expressing cells, but not shBAK expressing cells, failed to undergo cell death following exposure to ABT-263 (Figure 5D, top), indicating that BAX is essential to ABT-263-induced senolysis.
The above results prompted us to investigate the subcellular localization of BAX and BCL-X\textsubscript{L}, their interaction, and BAX conformational change/activation. The mitochondria-enriched lysates revealed the accumulation of BAX in cisplatin-induced senescent and further in ABT-263-treated HN30 cells (Figure 5E). In contrast, the amounts of BCL-X\textsubscript{L} and BAK at the mitochondria were only modestly perturbed (Figure 5E). We then investigated the BCL-X\textsubscript{L}/BAX interaction by co-immunoprecipitation experiments. When BCL-X\textsubscript{L} was immunoprecipitated, BAX was present in both the control and cisplatin treatment groups. However, when ABT-263 was introduced, the BCL-X\textsubscript{L}/BAX interaction was significantly decreased (Figure 5F), suggesting that ABT-263 inhibits the BCL-X\textsubscript{L}/BAX interaction and releases BAX from the complex. This result indicated that BAX became activated to allow apoptosis to occur.

**ABT-263 selectively eliminates cisplatin-induced mouse oral squamous cell carcinoma cells in vitro and in vivo**

In order to test the senolytic activity of ABT-263 in vivo, we first established the mouse oral squamous cell carcinoma (OSCC) cell line (602) derived from the 4-nitroquinoline-1 oxide (4NQO)-developed tumor on the tongue (see Materials and Methods). A crystal violet and senescence associated-\(\beta\)-galactosidase (SA-\(\beta\)-gal) stain revealed that cisplatin induced 602 cells into senescence and sensitized the cells to ABT-263 (Figure 6A). We then evaluated senolytic activity of ABT-263 in a syngeneic mouse model. Cisplatin treatment resulted in brief tumor stasis compared to the control and ABT-263 monotherapy (Figure 6B). Sequential cisplatin and ABT-263 treatment resulted in a distinct therapeutic benefit characterized by delayed tumor recurrence and longer survival (Figure 6B and 6C). Furthermore, two rounds of cisplatin followed by ABT-263 treatment (combination B) outperformed all groups, including the single round of cisplatin
followed by ABT-263 (combination A), in terms of delayed tumor recurrence and improved animal survival. Animal experiment diagram is presented in **Figure S4**.

We further extracted and analyzed the 602 tumors to evaluate markers of senescence and the senolytic activity of ABT-263. Cisplatin-induced senescence in tumors *in vivo* was clearly detected as X-gal staining with increased SA-β-gal activity, which was then decreased upon ABT-263 treatment (**Figure 6D, left panels**). Cisplatin also induces DNA single- or double-strand breaks (DSBs). The phosphorylated form of histone H2AX (γ-H2AX) marks sites of DNA DSB repair. Compared to the control, γ-H2AX was strongly stained in tumors exposed to cisplatin (**Figure 6D, middle panels**). However, ABT-263 did not appear to alter the levels of γ-H2AX either alone or in combination with cisplatin, both in the tumor bearing animal experiments (**Figure 6D**), and in the cell culture studies (**Figure S5**). Extensive cleavage of caspase-3 (c-casp3), indicative of apoptosis, was evident in tumors treated with cisplatin followed by ABT-263 (**Figure 6D, right panels**). These results suggest that the benefit of sequential treatment is a result of apoptosis caused by ABT-263 in cisplatin-induced senescent tumors.

Based on the previous preclinical data in animal models (Shoemaker *et al.*, 2006), ABT-263 treatment results in rapid and concentration dependent thrombocytopenia that resolves after drug cessation (Oltersdorf *et al.*, 2005; Roberts *et al.*, 2009). Here, we evaluated the safety of ABT-263 is our animal model by analyzing Complete Blood Counts (CBC), particularly by focusing on the dynamic of circulating platelets and neutrophils (**Figures 7 and S6**). The number of circulating platelets and neutrophils in the different groups of mice show that ABT-263 treatment alone or in combination with cisplatin does not result in thrombocytopenia or neutropenia in our experimental model system.
Discussion

Locoregional and distant recurrence are the most common cause of death in HNSCC patients, and it has been suggested that the morbidity and mortality is mediated by the progression from residual tumor cells that survive from the assault of chemotherapy or radiotherapy (Lambrecht et al., 2009). A similar contribution to recurrence from residual tumor cells is also observed in breast, prostate, and lung cancer; more specifically, whereas the initial therapies result in both tumor regression and stasis, a residual cell population can proliferate at secondary local or distant sites with equal or more aggressiveness (Morgan et al., 2009; Walens et al., 2019; Wu et al., 2020). This residual and dormant cell population could potentially be linked to senescent and quiescent tumor cells as well as cancer stem cells (Kim et al., 2012; Wang et al., 2017; Phi et al., 2018).

Despite the fact that therapy-induced senescence has been investigated for decades, the contribution of senescent tumor cells to disease recurrence is still obscure (Pérez-Mancera et al., 2014). The senescence phenotype was initially considered as a favorable outcome of cancer therapy, as it likely represents a primary response to chemotherapy or radiation and cells in this state manifest characteristics such as prolonged growth arrest, which may lead to tumor regression (Nardella et al., 2011). However, as senescent cells are metabolically active and resistant to apoptosis (Seluanov et al., 2001; Wiley et al., 2017), it is anticipated that the considerable heterogeneity of senescent tumor populations would allow for proliferative recovery of some tumor subpopulations from the state of growth arrest (Hernandez-Segura et al., 2017; Wiley et al., 2017). Additionally, the ability of senescent cells to secrete pro-inflammatory cytokines and chemokines (SASP) contributes to chronic inflammation and adverse paracrine effects (Krizhanovsky et al., 2008; Coppé et al., 2010). Finally, the tumorigenic potential and more
aggressive behavior of post-senescent cells, including frequent epithelium-to-mesenchymal transition (EMT) and genomic instability, argues for the central involvement of senescent cells in disease recurrence (Sieben et al., 2018). To combat these potentially deleterious long-term effects of therapy-induced senescence, a new class of compounds, termed “senolytics” which selectively induce cell death in senescent cells, has been developed (Sieben et al., 2018).

In the current work, we investigated the utility of a two-hit sequential treatment approach, first with chemotherapy followed by senolysis, in head and neck cancer. We chose p53 wild-type HN30 cell line derived from pharynx and p53-null HN12 cell line derived from lymph node metastasis (Singchat et al., 2016), in consideration of the fact that p53 is most commonly mutated in head and neck cancer patients (Leemans et al., 2011). Both cell lines showed a significant degree of senescence upon treatment with cisplatin by assessing multiple assays and markers (Figure 1). The delayed senescence in HN12 cell line likely reflects the p53-independent pathway (Mirzayans et al., 2012). For example, it has been shown that p16 plays a critical role in senescence induction in p53-null models (Mirzayans et al., 2012). We also confirmed senescence and tumor stasis induced by cisplatin treatment in a syngeneic mouse model (Figures 6B and 6D). Furthermore, the proliferative recovery from senescence was confirmed using fluorescence-activated cell sorting (FACS) and live cell imaging (Figure 2 and Videos) as well as in a mouse model (Figure 6B). These results further support the recent paradigm shift that therapy-induced senescence is transient, but not permanent, growth arrest, which may contribute to tumor recurrence from dormancy (Saleh, Bloukh, et al., 2020).

In order to overcome the survival mechanism which senescent cells maintain, our data indicates that a BCL-2/BCL-XL inhibitor, ABT-263 (navitoclax) efficiently induces apoptosis following cisplatin treatment in in vitro and in vivo head and neck cancer models (Figures 3 and
Figure 6D); these studies are consistent with previous reports showing effectiveness of ABT-263 in breast, lung, and prostate tumors (Zhu et al., 2015, 2016; Yosef et al., 2016; Grezella et al., 2018; Yabluchanskiy et al., 2020; Carpenter et al., 2021). We extensively investigated the selectivity of ABT-263, determining that this compound induces apoptosis only in the cisplatin-induced senescence population, but not in the proliferating population (Saleh, Carpenter, et al., 2020) (Figures 3, S2A, S2B, and S2C). Additionally, our growth curve data with multiple exposures to cisplatin after proliferative recovery confirms that ABT-263 shows selectivity for the cells that are exposed to a second dose of cisplatin after recovery, but not the population recovered from the first cisplatin exposure (Figure S2E).

In mechanistic studies, we showed that (i) BCL-X<sub>L</sub> is the primary target for apoptosis induce by ABT-263 in senescent cells (Figure 4), and that (ii) the inhibition of BCL-X<sub>L</sub>/BAX interaction by ABT-263 followed by BAX activation is critical for this apoptosis induction (Figure 5). We and others have shown that BCL-X<sub>L</sub> expression increases gradually after senescence induction (Hayward et al., 2003; Saleh, Carpenter, et al., 2020; Mas-Bargues et al., 2021) and the sensitization induced by ABT-263 is BCL-X<sub>L</sub>-dependent in breast and lung tumors (Saleh, Carpenter, et al., 2020). Our results indicate that BAX, but not BAK, is a critical pro-apoptotic protein for ABT-263-induced apoptosis in senescent cells in which the level of BCL-X<sub>L</sub> is induced and BAX is accumulated at the mitochondria. It has been shown that an increase of BCL-X<sub>L</sub> levels by overexpression leads to an increase of BAX at the mitochondria and sensitizes cells treated with ABT-737, a prototype BCL-2/BCL-X<sub>L</sub> inhibitor of ABT-263, to apoptosis (Renault et al., 2015). We speculate that the physiological levels of BCL-X<sub>L</sub> increased by senescence induction also led to BAX accumulation at the mitochondria, which shifts the dependency of ABT-263-induced apoptosis toward BAX. Consistently, studies have shown that BCL-X<sub>L</sub> is qualitatively and
quantitatively ten times more active than BCL-2 and is more effective in apoptosis inhibition (Wang et al., 2004; Fiebig et al., 2006). Moreover, the majority of head and neck cancer patients’ tumor biopsies have shown a significant up-regulation in BCL-XL but not BCL-2 protein levels. BCL-XL levels was shown to be directly associated with worse therapy outcomes, whereas BCL-2 positive tumors, even after locoregional metastasis, demonstrated better therapy outcomes (Pena et al., 1999). Carter et al also showed that BCL-XL is significantly overexpressed in head and neck cancer patients’ tumor samples, while BCL-2 levels does not show any increase (Carter et al., 2019). These data suggest that BCL-XL would play a major role, particularly in head and neck cancer, for drug sensitivity and treatment outcome. However, more additional work is needed to define the precise role(s) of BCL-XL and BCL-2, since our findings in this report along with publications in this area clearly show that BCL-2 and BCL-XL are functionally distinct.

Our data with a syngeneic mouse model (Figure 6) clearly indicate that two rounds of sequential cisplatin followed by ABT-263 treatment has a distinct therapeutic benefit with delayed tumor recurrence and longer survival. Cycling treatments with drugs and/or radiation are common procedure and often show clinical benefits. One concern regarding ABT-263 in the clinic is the thrombocytopenia that has been a predominant dose limiting toxicity as both a monotherapy and in combination. This has been managed successfully in several recent trials, allowing for tolerated and biologically active combinations with kinase inhibitors such as Osimertinib (Bertino et al., 2021) and ruxolitinib (Harrison et al., 2019). However, neutropenia has been reported as a dose limiting toxicity when navitoclax was administered with chemotherapy (Puglisi et al., 2011); this toxicity has been particularly limiting for these combinations, none of which have progressed beyond Phase 1. Our data indicate that sequential exposures to ABT-263 after cisplatin treatment can effectively reduce tumor burden, and therefore alleviate the need to dose both agents...
concomitantly. This sequential dosing approach thus has the potential to effectively treat head and neck cancer patients while circumventing the limiting hematological toxicity that would be anticipated by simultaneous dosing of the two agents. Next generation BCL-2/BCL-X<sub>L</sub> inhibitors such as AZD0466 (Patterson et al., 2021), APG-1252 (Lakhani et al., 2018), and DT2216 (BCL-X<sub>L</sub>-PROTAC) (He et al., 2020) have been designed to mitigate thrombocytopenia and clinical trials have recently started with these agents. Thus, these compounds also need to be verified as senolytics to be combined with existing chemotherapy/targeting drugs in the future. It is also imperative to determine the senolytic efficacy following chemoradiation, which is commonly used as the first line treatment for HNSCC patients.

Taken together, our study provides a clear foundation upon which to develop therapeutic approaches for senescence clearance to potentially prevent or delay cancer relapse in HNSCC. Additionally, our <em>in-vitro</em> and <em>in-vivo</em> data show that sequential treatment of cisplatin and navitoclax can provide a potentially effective treatment strategy with mitigated toxicity for HNSCC patients. However, there are still key questions that need to be answered in future studies, such as the mechanistic basis for recovery from senescence, and the potential interplay between navitoclax and the immune system. Furthermore, studies in progress suggest that navitoclax may not be effective in cisplatin-resistant head and neck cancer models; consequently, we are in the process of identifying alternative senolytic strategies for eliminating the resistant population as well as testing senolytics against chemoradiation, the standard of care in head and neck cancer.
Acknowledgments:

Tissue sectioning was provided by the VCU Tissue and Data Acquisition and Analysis Core (TDAAC) Facility. All flow cytometry data were generated at the VCU Massey Cancer Center Flow Cytometry Shared Resource.

Author Contributions:

Participated in research design: Gewirtz D, Harada H, Ahmadinejad F.

Conducted experiments: Ahmadinejad F, Bos T, Hu B, Britt E.

Contributed new reagents or analytic tools: Faber A, Koblinski J, Souers A, Leverson J.

Performed data analysis: Gewirtz D, Harada H, Ahmadinejad F, Bos T.

Wrote or contributed to the writing of the manuscript: Gewirtz D, Harada H, Ahmadinejad F, Bos T, Souers A.
References


Footnotes:

This research was supported in part by the National Institutes of Health R03 CA235097 (to H.H.), R01 CA239706 (to D.A.G. and H.H.) and the AADR Students Research Fellowship (to E.B.). Services and products generated by the VCU Massey Cancer Center Cancer Mouse Model Shared Resource were supported in part by funding from NIH/National Cancer Institute (NCI) Cancer Center Support Grant P30 CA016059.

A.J.S. and J.D.L. are employees and shareholders of AbbVie. A.C.F. is a paid consultant for AbbVie. Other authors have an actual or perceived conflict of interest with the contents of this article.
Figure 1. Cisplatin induces senescence-mediated growth arrest in HNSCC cells. A) Cell viability was monitored over a period of 12 days by trypan blue exclusion in HN30 and HN12 cells after 24 hours of exposure to 2, 5, and 10 µM cisplatin. B) Cell cycle analysis of HN30 and HN12 cells at Day 5 after treatment with 5 µM cisplatin for 24 hours. Cell cycle distribution is shown in the bar graphs. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 indicate statistical significance of each condition compared to control as determined using Student's t-test. C) Cells were analyzed for increased expression of SA-β-gal using X-gal (20x objective, scale bar: 20 µm, bright field images) or C12FDG (bar graphs) and increased SAHF formation by H3K9ME3 immunofluorescence (100x objective, scale bar: 5 µm, fluorescent images). Blue fluorescence indicates nuclear staining with DAPI, and green fluorescence reflects H3K9Me3 immunostaining. Staining was performed 5 days after treatment with 5 µM cisplatin for 24 hours. D) Western blotting for p53 and p21 in HN30 and HN12 cells at the indicated time points after cisplatin treatment. E) qRT-PCR for the SASP mRNAs IL-6, IL-8, and IL-1β. RNA was extracted at Day 5 following cisplatin exposure. All images are representative fields or blots from at least three independent experiments, and all quantitative graphs are mean ± SD from at least three independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 indicate statistical significance of each condition compared to control as determined using two-way ANOVA with Sidak's post hoc test. All images are representative fields or blots from three independent experiments (n = 3).
Figure 2. Proliferative recovery from cisplatin treatment in HN30 and HN12 cells is associated with the reduction of senescence-associated features. A) Histochemical SA-β-gal staining (20x objective, scale bar: 20 µm, bright field images). Cells were treated with 5µM cisplatin for 24 hours and stained for SA-β-gal activity at days 10 and 14. Note that the enzyme activity declines with cellular proliferative recovery. B) qRT-PCR for the SASP mRNAs IL-6, IL-8, and IL-1β. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 indicate statistical significance of each condition compared to control as determined using two-way ANOVA with Sidak's post hoc test. C) Growth curve and D) SA-β-gal staining for high-C12FDG-positive HN30 and HN12 cells (enriched on Day 5 after cisplatin treatment).
**Figure 3. ABT-263 induces apoptotic cell death in cisplatin-induced senescent cells.**

A) Growth curves for cells treated with cisplatin followed by either vehicle or 2 μM ABT-263 for 24 hours. Arrows indicate the time of ABT-263 treatment. B) Annexin-V/PI quantification of apoptosis induced by 2 μM ABT-263 with overnight exposure 24 hours after drug removal (Day 7) in HN30 and HN12 cells after treatment with cisplatin. C) Western blots for cleaved-caspase 3 in HN30 and HN12 cells. Cells were treated with 5μM cisplatin followed by ABT-263 for 24 hours and harvested at day 7. All images are representative fields or blots from at least three independent experiments, and all quantitative graphs are mean ± SD from at least three independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 indicate statistical significance of each condition compared to control as determined using two-way ANOVA with Sidak's post hoc test.
Figure 4. BCL-XL is the primary target for ABT-263-induced senolysis. Growth curves for A) HN30 and B) HN12 cells treated with 5uM cisplatin followed by either vehicle, 2 µM A-1155463 (Left) or ABT-199 (Right) for 24 hours. Arrows indicate timepoints of A-1155463 or ABT-199 treatment. C) and D) Apoptotic cell death was determined in HN30 and HN12 cells, respectively, by Annexin-V/PI staining followed by FACS analysis. *** p ≤ 0.001, **** p ≤ 0.0001 indicate statistical significance of each condition compared to indicated condition as determined using two-way ANOVA with Sidak's post hoc test.
Figure 5. ABT-263 induces senolytic activity through modulation of the BAX/BCL-X<sub>L</sub> interaction. A) HN30 cells were treated with cisplatin and harvested at the indicated times. B) HN12 cells were treated with 5uM cisplatin and harvested at Day 7. Total cell lysates were subjected to Western blotting with the indicated antibodies. C) HN30 shBAX, shBAK and shC (scrambled control) cells were treated with cisplatin (5 µM) for 5 days. Total cell lysates were subjected to Western blotting with the indicated antibodies. D) Senescent cells in (C) were treated with ABT-263, ABT-199, A-1155463 (1 µM each) for 24 hours and stained with trypan blue and X-gal activity. (10x objective, scale bar: 10 µm, bright field images). E) BAX is recruited to the mitochondria membrane upon ABT-263 treatment. HN30 cells were treated with cisplatin (5 µM) for 5 days followed by ABT-263 (1 µM) for 16 hours. The earlier time point allowed us to detect navitoclax effects on apoptosis regulatory proteins before apoptosis completion, which might have resulted in the degradation of select proteins. Mitochondria-enriched (heavy membrane) fractions were subjected to Western blotting with the indicated antibodies. F) ABT-263 disrupts the interactions of BCL-X<sub>L</sub> and BAX. HN30 cells were treated as in (E), and total cell lysates were immunoprecipitated with anti-BCL-X<sub>L</sub> antibodies followed by Western blotting with the indicated antibodies. All images are representative fields or blots from three independent experiments (n = 3), and all quantitative graphs are mean ± SD from three independent experiments (n = 3).
Figure 6. Sequential administration of ABT-263 following cisplatin delays tumor recurrence in a syngeneic mouse model of OSCC. A) ABT-263 eliminates cisplatin-induced senescent mouse OSCC cells in vitro. Mouse OSCC 602 cells were treated with cisplatin (2.5 μM, the dose efficiently induces senescence in this cell line) for 5 days followed by exposure to ABT-263 (1 μM) for 24 hours. Cells were stained with trypan blue to investigate ABT-263 effectiveness. X-gal staining in SA-β-gal positive cells indicates senescence after cisplatin treatment. (10x objective, scale bar: 10 μm, bright field images). B) 602 cells were subcutaneously inoculated in C57BL/6 mice at the flank (Day 0). When tumors achieved a size of ~100 mm3, mice were randomized into five groups (Day 13, N=6/group). Mice were treated with cisplatin (5 mg/kg) at Day 13, 16, 20 and 23, followed by ABT-263 (80 mg/kg) daily at Day 27-31 and Day 34-38. The second round of treatments was performed with cisplatin at Day 41, 44 and 48, followed with ABT-263 at Day 55-59 and Day 62-66. Tumor volume (B) was determined by caliper measurements and survival (C) was monitored by Kaplan-Meier curves. D) Tumors were excised after treatment with vehicle (control), cisplatin, ABT-263 or cisplatin followed by ABT-263. SA-β-gal activity was monitored by staining with X-gal, and DNA double-strand breaks repair and apoptosis were monitored by immunohistochemical staining with antibodies against γ-H2AX and cleaved-caspase-3, respectively (Original magnification = 20X). Graphs are represented as mean ± SEM. All tumor images are representative fields from four tumor slices (n = 3) taken from three mice per group (n = 3).
Figure 7. Platelet cell count (K/µl) in mice treated with A) vehicle, B) cisplatin alone, C) ABT-263 alone or D and E) in combination with cisplatin over a period of 21 days. Control vs ABT, cisplatin, Combination A or B: p > 0.05 as determined using two-way ANOVA with Sidak's post hoc test. All quantitative graphs are mean ± SD from at least three independent experiments.
Figure 2

A. Control, Cis, D10, Cis, D14

B. HN30 and HN12 graphs showing fold change for IL-8, IL-6, and IL-1β.

C. Graphs showing the number of viable cells for HN30 and HN12 sorted cells and controls.

D. Images of HN30 at Day 8, Day 10, Day 12, and Day 14.
Figure 3

A

HN30

*control
HN30 5µM cis
ABT 263
Cis + ABT 263

Num. of viable cells X 10^4
Day 0  Day 3  Day 6  Day 9  Day 12  Day 15  Day 18

HN12

Control
Cisplatin 5µM
ABT 263
Cis + ABT 263

Num. of viable cells X 10^4
Day 0  Day 3  Day 6  Day 9  Day 12  Day 15  Day 18

B

HN30

HN12

Apoptotic cells %

Control  ABT 263  Cisplatin  Cis + ABT 263

Apoptotic cells %

Control  ABT 263  Cisplatin  Cis + ABT 263

C

HN30

Cisplatin D7

ABT-263 +

Cleaved Caspase 3
GAPDH
19 kDa
17 kDa
36kDa

HN12

Cisplatin D7

ABT-263 +

Cleaved Caspase 3
GAPDH
19 kDa
17 kDa
36kDa
Figure 7

A. Control

B. Cisplatin

C. ABT-263

D. Combination A

E. Combination B